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Lifestyle measures plus antihypertensive drug therapy
should be used to treat adults with hypertension (1-4).
Adults with clinical cardiovascular disease (coronary
heart disease, heart failure, and stroke) should have
their blood pressure reduced below 130/80 mmHg for
secondary prevention of recurrent cardiovascular disease
events (4). The blood pressure should be reduced below
130/80 mmHg for primary prevention of cardiovascular
disease in adults with an estimated 10-year risk of
atherosclerotic cardiovascular disease ≥10% (4,5). The
blood pressure should be reduced below 140/90 mmHg for
primary prevention of cardiovascular disease in adults with
an estimated 10-year risk of atherosclerotic cardiovascular
disease less than 10% (4,5). Initiate antihypertensive drug
treatment with 2 first-line drugs from different classes
either as separate drugs or in a fixed-dose combination in
adults with a blood pressure of ≥140/90 mmHg or with a
blood pressure >20/10 mmHg above their blood pressure
target (4).
The first antihypertensive drug administered to white
and other non-black adults younger than 60 years of age
with primary hypertension, should be an angiotensinconverting enzyme (ACE) inhibitor or angiotensin receptor
blocker (4,6). The second drug should be a thiazide
diuretic (preferably chlorthalidone) or a calcium channel
blocker. If a third antihypertensive drug is needed to
control the hypertension, an ACE inhibitor or angiotensin
receptor blocker plus a thiazide diuretic plus a calcium
channel blocker should be administered (4,6). The first
antihypertensive drug administered to white and other nonblack adults aged 60 years of age and older with primary
hypertension should be a thiazide diuretic (preferably
chlorthalidone) or a calcium channel blocker (4,6). If a third
antihypertensive drug is needed to control the hypertension,
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a thiazide diuretic plus a calcium channel blocker plus an
ACE inhibitor or angiotensin receptor blocker should
be administered (4,6). The first antihypertensive drug
administered to adult blacks with primary hypertension
should be a thiazide diuretic (preferably chlorthalidone) or
a calcium channel blocker (4,6). if a third antihypertensive
drug is needed to control the hypertension, a thiazide
diuretic plus a calcium channel blocker plus an ACE
inhibitor or angiotensin receptor blocker should be
administered (4,6).
Adults with hypertension and stable coronary heart
disease should be treated with a beta blocker plus an ACE
inhibitor or angiotensin receptor blocker (1,3,4,7-14).
If a third antihypertensive drug is needed to control the
hypertension, a beta blocker plus an ACE inhibitor or
angiotensin receptor blocker plus a thiazide diuretic or
a calcium channel blocker should be administered. If a
fourth antihypertensive drug is required to adequately
control the hypertension, an aldosterone antagonist should
be administered (4). In persons with stable ischemic heart
disease who have angina pectoris despite beta blocker
treatment and persistent uncontrolled hypertension,
a dihydropyridine calcium channel blocker should be
added (1,3,4,7,8,15). The beta blockers that should be
administered for treatment of hypertension in patients with
coronary heart disease include carvedilol, metoprolol tartrate,
metoprolol succinate, bisoprolol, nadolol, propranolol, and
timolol (4). Atenolol should not be used (1,3,4,9,16,17).
The nondihydropyridine calcium channel blockers
verapamil and diltiazem are contraindicated if left
ventricular systolic dysfunction is present (1,3,4). Carvedilol,
metoprolol succinate, or bisoprolol are the beta blockers
to be administered if left ventricular systolic dysfunction is
present (1,3,4,8,9).
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If patients with an acute coronary syndrome have
hypertension after therapy with a beta blocker plus an
ACE inhibitor or angiotensin receptor blocker, a longacting dihydropyridine calcium channel blocker such as
amlodipine or felodipine should be added to the therapeutic
regimen (1,3). Aldosterone antagonists should be
administered to patients treated with beta blockers plus ACE
inhibitors or angiotensin receptor blockers after myocardial
infarction with left ventricular systolic dysfunction and heart
failure or diabetes mellitus if their serum potassium is below
5.0 meq/L and if their serum creatinine is ≤2.5 mg/dL in
men and ≤2.0 mg/dL in women (1,3,4,18).
Patients with hypertension and heart failure with a
decreased left ventricular ejection fraction should be treated
with carvedilol, metoprolol succinate, or bisoprolol plus an
ACE inhibitor or angiotensin receptor blocker or preferably
an angiotensin receptor-neprilysin inhibitor plus a diuretic
and if needed with an aldosterone antagonist (1,3,4,9,18,19).
Nondihydropyridine calcium channel blockers are
contraindicated in persons with heart failure and a reduced
left ventricular ejection fraction (1,3,4,19,20).
Patients with hypertension and heart failure with a
preserved left ventricular ejection fraction should have
their volume overload managed with diuretics, their
comorbidities treated, and their hypertension treated with a
beta blocker plus an ACE inhibitor or angiotensin blocker
plus an aldosterone antagonist (3,4,19,21,22).
Hypertensive adults with chronic kidney disease
stage 3 or higher or stage 1 or 2 chronic kidney disease
with albuminuria 300 mg and more per day should be
administered an ACE inhibitor to slow progression of
their chronic kidney disease (4,23-26). If an ACE inhibitor
is not tolerated, these patients should be administered an
angiotensin receptor blocker (4). Patients who have stage
1 or 2 chronic kidney disease without albuminuria may be
administered usual first-line antihypertensive drugs (4). If
3 antihypertensive drugs are needed, these patients should
be given an ACE inhibitor or angiotensin receptor blocker
plus a thiazide diuretic plus a calcium channel blocker. After
kidney transplantation, hypertension should be treated with
a calcium channel blocker to improve glomerular filtration
rate and kidney survival (4,27).
Hypertensive patients with a prior stroke or transient
ischemic attack should be administered a thiazide diuretic
or ACE inhibitor or angiotensin receptor blocker (4,28,29).
If a third antihypertensive drug is needed, these patients
should be given a thiazide diuretic plus an ACE inhibitor or
angiotensin receptor blocker plus a calcium channel blocker.
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Hypertensive patients with peripheral arterial
disease should receive usual first-line antihypertensive
drugs (4,30). There are no data showing that any one class of
antihypertensive drugs is superior for treating hypertension
in patients with peripheral arterial disease (4,30).
Thiazide diuretics, ACE inhibitors, angiotensin receptor
blockers, and calcium channel blockers may be used as initial
therapy in hypertensive diabetics (4,31-33). ACE inhibitors
or angiotensin receptor blockers should be administered to
hypertensive diabetics with persistent albuminuria (4,34).
The ALLHAT study found that chlorthalidone was better
than lisinopril, amlodipine, and doxazosin in reducing
cardiovascular disease and renal outcomes in nondiabetics
with hypertension and the metabolic syndrome (4,35).
Beta blockers are the preferred antihypertensive drugs in
hypertensive patients with a thoracic aortic aneurysm (4,36).
Beta blockers also improve survival in patients with type
A and with type B acute and chronic thoracic aortic
dissection (4,37,38). If thoracic aorta dissection develops,
beta blockers are the initial drug of choice for decreasing
blood pressure, ventricular rate, dP/dt, and stress on the
aorta (36,39). Systolic blood pressure should be reduced
to 100 to 120 mmHg and the ventricular rate decreased to
lower than 60 beats/minute by intravenous propranolol,
metoprolol, labetalol, or esmolol (36).
Pregnant women with hypertension should not be
administered an ACE inhibitor, angiotensin receptor
blocker, direct renin inhibitor, or atenolol because these
drugs are fetotoxic (4,40,41). Pregnant women with
hypertension should be treated with methyldopa, nifedipine,
and/or labetalol (4,40,41).
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